WO2005116241A1 - 哺乳動物細胞の性質判定方法及びこれを用いた癌の診断方法 - Google Patents
哺乳動物細胞の性質判定方法及びこれを用いた癌の診断方法 Download PDFInfo
- Publication number
- WO2005116241A1 WO2005116241A1 PCT/JP2005/009847 JP2005009847W WO2005116241A1 WO 2005116241 A1 WO2005116241 A1 WO 2005116241A1 JP 2005009847 W JP2005009847 W JP 2005009847W WO 2005116241 A1 WO2005116241 A1 WO 2005116241A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cdk
- cyclin
- dependent kinase
- ratio
- specific activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Definitions
- the present invention relates to a method for determining the properties of mammalian cells and a method for diagnosing cancer using the same.
- the present invention relates to the sensitivity to stimulants such as cancer, tumor malignancy, and anticancer drugs, based on the ratio between the activity level of CDK, including the specific activity of cyclin-dependent kinase (CDK), and the expression level.
- the present invention relates to a method for determining sex and a method for diagnosing cancer using the method. Background art
- Tumor markers are substances such as proteins, glycoproteins, and lipids that are expressed in tumor cells by genes that are no longer expressed during the development and maturation of individuals. Serum diagnosis detects tumor markers. By doing so, the stage and malignancy of the tumor are determined. However, many of the currently used tumor markers are not very specific for cancer. In early cancers, the expression sensitivity is low because the expression level is very small. For these reasons, at present, the reliability of cancer diagnosis using tumor markers is not so high in medical practice.
- TNM classification has been devised as a method for standardizing diagnostic methods, and is being diverted worldwide.
- the TNM classification of cancer is a method used by the International Union for Cancer Research (UICC) to describe the degree of malignancy progression, where "T” is the size of the primary tumor, ⁇ is the level of lymph metastasis, and ⁇ is the distant metastasis. Is shown. Then, for ⁇ , the degree of progress is classified into 1 (the extent to which the tumor is localized in the tissue) to 4 (the extent to which tumor formation outside the tissue appears). The degree of progress was classified into 0 (no local lymph node metastasis) to 3 (nodal metastasis was histologically recognized).
- the grade was 0 (no distant metastasis) to 1 (distant metastasis). Metastasis). The larger the value in any of T, ⁇ , and ⁇ , the lower the prognosis and the higher the grade of malignancy.
- Such ⁇ classification is generally used because it is useful for decision of treatment and prognosis. However, even in patients who are judged to have early cancer by ⁇ classification, about 10 At present, ⁇ 20% of patients will relapse due to distant metastases and die within 5 years, which is a major clinical problem. In addition, ⁇ judgment based on classification can grasp the pathological condition at the time of diagnosis, but has not yet been able to accurately predict the prognosis.
- Patent Document 1 proposes a diagnostic method using the expression levels of CDK1 and CDK4 in a sample and, if necessary, the p53 mutation status as an index.
- Patent Document 2 proposes a method for diagnosing cancer and precancerous conditions using overexpression of CDK4, CDK6, and cyclin-dependent kinase inhibitor (CDK inhibitor) as an index.
- Cyclin-dependent kinase (CDK) expression is known to be high and high in cells in which growth is induced by growth factors, but is generally present in a certain amount in cells. In addition, it shows activity at a specific stage of the cell cycle according to the type of CDK because it is bound to a cyclin molecule to form a complex of CDK and cyclin after being subjected to an activity such as phosphoridation. It is also known that CDK inhibitors bind to CDK and Z or cyclin'CDK complexes and inhibit CDK activity. Thus, since the actual regulation of the cell cycle is complicated, a mere judgment based on the expression levels of CDKs, cyclins, and CDK inhibitors is not sufficient as an indicator of the regulation state of the cell cycle.
- Patent Document 3 discloses a diagnostic method using CDK activity as an indicator of cancer malignancy, and a method of measuring CDK activity without using a radioactive substance, in consideration of the binding to cyclin and the effects of inhibitors. It has been disclosed. However, the data on the activity measured by this method does not have sufficient diagnostic accuracy to substitute for cancer diagnosis currently performed in clinical practice.
- MTT Atssay method means that MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) is present in mitochondria when incorporated into living cells. That can be cleaved by reductase (succinate dehydrogenase), which is not able to cleave MTT in dead cells.
- Non-Patent Document 1 It is reported to be 5% (Non-Patent Document 1).
- the above-mentioned deviation method also has a positive prediction rate of less than 70%, which is insufficient as an index for judging whether or not it is possible to take the anticancer drug treatment.
- Patent Document 1 Japanese Patent Application Publication No. 2002-504683
- Patent Literature 2 JP-T 2002-519681
- Patent Document 3 Japanese Patent Application Laid-Open No. 2002-335997
- Non-patent document l Weisenthal, L.M. and Nygren.P (2002) Current status of cell culture drug resistance testing (CCDRT) ⁇ http: / / linithal.org/ oncol- t.htm
- the present invention has been made in view of the above-mentioned circumstances, and an object of the present invention is to determine the degree of malignancy of cancerous tissues in the clinic (small metastasis, poor recurrence, poor prognosis). Another object of the present invention is to provide a judgment method capable of making an accurate and stable judgment by eliminating a variation in diagnosis between medical institutions and individuals, and a method of molecular diagnosis of cancer using the method.
- the sensitivity of mammalian cells to stimulants such as anticancer drugs can be used as an index for determining whether to take drug treatment such as anticancer drug treatment. High !, also provides a judgment method.
- the present inventors focused on the specific activity of cyclin-dependent kinases and conducted various studies on the relationship with tissue pathological judgment. As a result, the specific activities of two types of cyclin-dependent kinases (CDKs) or their specific activities were examined. They found that there was a high correlation between the CDK profile, including the reciprocal, and the cell proliferation ability and tissue malignancy (relapse), and completed the method for determining the properties of the present invention. I let you. The inventors also found that the sensitivity of mammalian cells to stimulants was correlated with the two types of CDK profiles, and completed the method for determining sensitivity according to the present invention.
- CDKs cyclin-dependent kinases
- the method for determining the properties of a mammalian cell of the present invention includes the ratio of the activity value and the expression level of the first cyclin-dependent kinase (first CDK) and the second cyclin-dependent kinase in a mammalian cell. This is a method for judging the above-mentioned properties of mammalian cells based on a CDK profile including a ratio between the activity value and the expression level of ze (second CDK).
- the property may be determined by comparing the CDK profile with a CDK profile of a standard cell.
- the property of the mammalian cell may be determined by comparing the ratio of the activity value of the dependent kinase (second CDK) to the expression level (A2) with a predetermined threshold value corresponding to the ratio.
- the cyclin-dependent kinase is preferably selected from the group consisting of CDK1, CDK2, CDK4, CDK6, cyclin A-dependent kinase, cyclin B-dependent kinase, and cyclin D-dependent kinase, and more preferably.
- the first cyclin-dependent kinase is CDK1
- the second cyclin-dependent kinase is CDK2.
- the property may be the proliferative ability of the mammalian cell or the malignancy of the mammalian cell.
- the malignancy includes the metastasis, recurrence, and poor prognosis.
- the metastasis includes lymph node metastasis and distant metastasis.
- the method for diagnosing cancer of the present invention is a method for diagnosing the malignancy of a cancer based on the above-described determination method of the present invention for cells from which the strength of a living tissue has also been collected.
- the method for determining the sensitivity of a mammalian cell to a stimulant includes the step of determining the ratio between the activity value and the expression level of a first cyclin-dependent kinase (first CDK) in a mammalian cell and the second cyclin-dependent kinase. Based on the CDK profile including the ratio between the activity value and the expression level of the kinase (second CDK), the sensitivity of the cells to the stimulator is determined.
- first CDK first cyclin-dependent kinase
- second CDK Based on the CDK profile including the ratio between the activity value and the expression level of the kinase
- the first cyclin-dependent kinase (second The ratio between the activity value and the expression level of (1CDK) (A1) and the ratio of the activity value and the expression level of the second cyclin-dependent kinase (second CDK) (A2) corresponds to the ratio.
- the cyclin-dependent kinase is preferably selected from the group consisting of CDK1, CDK2, CDK4, CDK6, cyclin A-dependent kinase, cyclin B-dependent kinase, and cyclin D-dependent kinase.
- the stimulating substance is preferably selected from a growth factor, an anticancer agent, and a mutagenic substance.
- the CDK profile referred to in the present specification refers to the ratio (eg, specific activity) between the activity value and expression level of at least one kind of CDK possessed by a certain cell, the activity value of Z or a plurality of CDKs, Numerical value calculated from the present amount (for example, the ratio of the activity value of the first CDK to the expression level (A1) and the ratio of the activity value of the second CDK to the expression level (A2) (for example, A1ZA2 or A2ZA1 ) Etc.).
- the ratio eg, specific activity
- Numerical value calculated from the present amount for example, the ratio of the activity value of the first CDK to the expression level (A1) and the ratio of the activity value of the second CDK to the expression level (A2) (for example, A1ZA2 or A2ZA1 ) Etc.
- CDK cyclin-dependent kinase
- CDK specific activity CDK activity value, CDK expression level
- the CDK activity value is a unit based on the mass of the phosphorylated substrate, and is a value obtained from the actual measurement value of the cell-containing sample and the activity value of the standard product (versus the activity value).
- the expression level of CDK refers to the amount (unit of molecular number) of CDK present in an actual cell-containing sample.
- the term “easiness of metastasis” in the present invention refers to the high probability that cancer cells move from a primary focus to a distant tissue and form a metastatic focus. High probability! ⁇ It is known that the biological characteristics (ease of metastasis) of cancer cells are indicated by their invasive and migratory abilities.
- the likelihood of recurrence refers to the frequency of recurrence of a cancer patient group classified according to a certain classification (eg, stage classification). For example, Stage III has a 50% recurrence rate and Stage II (Relapse rate) (20%).
- Poor prognosis refers to the frequency of death within 5 or 10 years of a group of cancer patients classified according to a certain classification (eg, stage classification). For example, stage III has a mortality rate of 50%, and is said to have died and a poor prognosis sooner than stage II (mortality rate of 20%).
- stage III has a mortality rate of 50%, and is said to have died and a poor prognosis sooner than stage II (mortality rate of 20%).
- the specific activity is used as an index to avoid errors and noise due to the method for preparing the measurement sample.
- the CDK specific activity profile that takes into account the specific activities of the two CDKs, and particularly the ratio of the specific activities of the two CDKs, which is used as a judgment index in the present invention, is determined based on the ratio of the cells present in the cell cycle, Since it is highly correlated with cancer and other properties such as several media, highly reliable molecular diagnosis is possible.
- the index based on the cell cycle since the index based on the cell cycle is used, it is possible to judge the biological characteristics of the current cell, clinical characteristics (typically malignancy) that can be determined only by their characteristics, drugs such as anticancer drugs, and external stimulation. It is also possible to determine the susceptibility or the resistance to. Especially in the determination of susceptibility, the rate of correct answers for the determination of susceptibility (positive) is high, so when taking anticancer drug treatment, it is excellent as a criterion!
- FIG. 1 is a diagram for explaining a cell cycle.
- FIG. 2 is a view showing the results of measuring the DNA content of various cultured cells.
- FIG. 3 is a view for explaining the results of DNA content data.
- FIG. 4 is a graph showing the abundance ratio of various culture cells in the S phase.
- FIG. 5 is a graph showing measurement results of CDK1 specific activity and CDK2 specific activity of various cultured cells.
- FIG. 6 is a view showing a CDK specific activity profile of a specimen determined as low risk among tissues derived from a breast cancer patient.
- FIG. 7 is a view showing a CDK specific activity profile of a specimen determined as high risk among tissues derived from a breast cancer patient.
- FIG. 8 is a graph showing the measurement results of CDK1 specific activity and CDK2 specific activity of breast cancer patients A to I.
- Breast cancer patients AI receive treatment with the anticancer drug docetaxel, The change in size was examined.
- FIG. 9 is a graph showing the measurement results of CDK1 specific activity and CDK2 specific activity of breast cancer patients J to P.
- Breast cancer patients JP received treatment with the anticancer drug paclitaxel, and the change in tumor size after administration was examined.
- the method of the present invention for determining the properties of a mammalian cell comprises measuring the expression level and activity of two or more cyclin-dependent kinases in the mammalian cell, and determining the activity of the first cyclin-dependent kinase.
- This is a method for determining the properties of the mammalian cell based on a CDK profile including a ratio between the expression level and the ratio between the expression value and the activity value of the second cyclin-dependent kinase.
- the mammal targeted by the determination method of the present invention is not particularly limited, but the determination method of the present invention requires determination of a human, particularly a clinical condition, more specifically, a condition for cancer. Useful for humans.
- the cells targeted by the method of the present invention include mammalian living tissues, that is, supporting tissues such as fibrous connective tissues, cartilage tissues, bone tissues, blood, and lymph; epithelial tissues; muscle tissues; Cells that break the harmony as an individual and cause abnormalities in the control mechanism of proliferation! / Obtained pathological information, such as tumor cells in rutile tissue! is there .
- mammalian living tissues that is, supporting tissues such as fibrous connective tissues, cartilage tissues, bone tissues, blood, and lymph; epithelial tissues; muscle tissues; Cells that break the harmony as an individual and cause abnormalities in the control mechanism of proliferation! / Obtained pathological information, such as tumor cells in rutile tissue! is there .
- tumor cells that can be located in breast, lung, liver, stomach, large intestine, spleen, skin, uterus, testis, ovary, thyroid, parathyroid, lymphatic system, bone marrow and the like are suitable targets.
- These cells may be cells obtained by directly collecting the power of the corresponding biological tissue, or cells obtained by separating the power of excretion from the living body such as urine and sputum. Alternatively, subcultured cells may be used. When it is desired to obtain information on cancer, cells collected from tumor tissue are preferably used.
- the properties of the mammalian cell to be determined include the proliferation ability and malignancy of the cell to be measured.
- the proliferative capacity of a cell refers to the level of proliferative activity of the cell, the power of abnormalities in the control mechanism of proliferation (presence or absence of canceration), and information on aneuploidy.
- the malignancy of a cell refers to the severity of metastasis, recurrence, poor prognosis, etc. No.
- recurrence refers to the case where the same malignant tumor is reproduced in the remaining organ after partial resection of the organ in order to remove the malignant tumor, or the case where tumor cells are separated from the primary tumor and distant tissue (distant tissue). (Organ)), where it grows autonomously there (metastatic recurrence).
- distal tissue distant tissue
- metastatic recurrence Generally, if recurrence is observed within 5 years, it is said to be “prone to recurrence”.
- stage III has a recurrence rate of 50%, which is more likely to occur than stage II (relapse rate of 20%).
- Prognosis is the prediction of the course and end of the disease.The higher the mortality after 5 or 10 years, the worse the prognosis.For example, stage III has a mortality of 50% and stage II has a mortality of 20%. The prognosis is worse.
- the cyclin-dependent kinase is a generic term for a group of enzymes that are activated by binding to cyclin, and function at a specific time in the cell cycle according to the type.
- CDK inhibitor is a generic term for a group of factors that bind to the cyclin'CDK complex and inhibit its activity.
- the cell cycle which is the cycle from the start of proliferation of a cell, through events such as DNA replication, chromosome distribution, nuclear division, and cytokinesis, to becoming two daughter cells and returning to the starting point, is as follows: As shown in Figure 1, there are four phases: G1, S, G2, and M phases.
- the S phase is the DNA replication phase
- the M phase is the mitotic phase.
- the G1 phase is a preparatory inspection period from the completion of mitosis to the start of DNA synthesis to enter the M phase. Beyond the critical point in the G1 phase (point R in animal cells), the cell cycle starts and usually goes around without stopping.
- the G2 phase is also the end of DNA synthesis and the start of mitosis.
- the major checkpoints in the cell cycle are the G1 phase and the G phase phase, just before entering the S phase.
- the G1 checkpoint is especially important because it triggers the start of the S phase. This is because beyond a certain point in the G1 phase, the cell progresses through the cell cycle in the order of S ⁇ G2 ⁇ M ⁇ G1 without stopping proliferation even if the proliferation signal is lost.
- the cells that have stopped growing have a resting phase (GO) with a G1 phase DNA content and are out of the cell cycle. Induction of proliferation allows the cells to progress to the S phase a little longer than the G1 phase in the cell cycle.
- the cyclin-dependent kinase (CDK) used in the method of the present invention is selected from the group consisting of CDK1, CDK2, CDK4, CDK6, cyclin A-dependent kinase, cyclin B-dependent kinase, and cyclin D-dependent kinase.
- Cyclin A dependence Sex kinases are CDKs that show activity by binding to cyclin A and, as currently known, refer to both CDK1 and CDK2.
- Cyclin B-dependent kinase is a CDK that shows activity by binding to cyclin B, and CDK1 corresponds to what is currently known.
- Cytalin D-dependent kinase refers to a CDK that binds to cytalin D and shows activity.
- both CDK4 and CDK6 correspond.
- CDKs are now known to have a cyclin-CDK complex bound to the corresponding cyclin (hereinafter sometimes referred to as "active CDK").
- active CDK the specific period of the cell cycle as shown in Table 1 is activated.
- CDK1 binds to cyclin A or B
- CDK2 binds to cyclin A or E
- CDK4 and CDK6 bind to cyclin D1, D2, or D3 to become active.
- CDK activity may be inhibited by CDK inhibitors as shown in Table 1.
- p21 inhibits CDK1,2, p27 inhibits CDK2,4,6 and pl6 inhibits CDK4,6.
- CDK specific activity CDK activity value
- CDK expression level CDK expression level
- CDK profile examples include a profile containing CDK specific activity (CDK specific activity profile) and a profile containing the reciprocal of CDK specific activity (reciprocal profile of CDK specific activity).
- the CDK activity value refers to the number of substrates that bind to a specific cyclin (for example, activated CDK1, activated CDK2 is histone Hl, activated CDK4 and activated CDK6 are Rb (retinoblastoma)
- activated CDK1 activated CDK2 is histone Hl
- activated CDK4 and activated CDK6 are Rb (retinoblastoma)
- the ability to phosphorylate a protein (Retinoblastoma protein)) and the level of enzymatic kinase activity (unit is expressed in U (unit)) can be measured by a conventionally known enzyme activity measuring method.
- papermaking samples containing cell lysate mosquito ⁇ Luo activated CDK of the measurement sample tone, 32 P-labeled ⁇ ( ⁇ - [32 P] - ATP) using the 32 P into the substrate protein There is a method that measures the amount of labeled phosphorylation substrate after incorporation and quantifies it based on a calibration curve created with a standard product.
- a method without using a radioactive label a method disclosed in JP-A-2002-335997 can be mentioned.
- the cell-solubility of the measurement sample is determined by preparing a sample containing the desired activated CDK and reacting adenosine 5, -0- (3-thiotrifosfate) (ATP- ⁇ S) with the substrate.
- a monothiophosphate group is introduced into the serine or threonine residue of the substrate protein, and a labeling fluorescent substance or a labeling enzyme is bound to the sulfur atom of the introduced monothiophosphate group to label the substrate protein.
- This method measures the labeling amount of the obtained thiophosphoric acid substrate (the amount of fluorescence when a labeled fluorescent substance is used) and quantifies it based on a calibration curve created with a standard product.
- a sample to be used for activity measurement is prepared by specifically collecting a target CDK from a soluble solution of cells to be measured.
- a target CDK from a soluble solution of cells to be measured.
- it may be prepared using an anti-CDK antibody specific for the target CDK, or may be prepared using a specific cyclin-dependent kinase (for example, cyclin-dependent kinase, cyclin B-dependent kinase, cyclin E-dependent kinase).
- a specific cyclin-dependent kinase for example, cyclin-dependent kinase, cyclin B-dependent kinase, cyclin E-dependent kinase.
- an anti-cyclin antibody for activity measurement, use an anti-cyclin antibody to prepare.
- the sample will contain CDKs other than the active CDK.
- a complex in which a CDK inhibitor is bound to a cyclin'CDK complex is also included.
- an anti-CDK antibody When an anti-CDK antibody is used, it includes CDK alone, a complex of CDK and cyclin and Z or a CDK inhibitor, and a complex of CDK and another compound. Therefore, the activity value is determined by the active, inactive, and various competitive reactions. It is measured as phosphorylated substrate units (U) under mixed conditions.
- the CDK expression level is a target CDK level (a unit corresponding to the number of molecules) for which the cell solubilizability is also measured, and is a conventionally known method for measuring the target protein level from a protein mixture. Can be measured. For example, an ELISA method, a Western blot method, or the like may be used, or the measurement may be performed by the method disclosed in JP-A-2003-130871.
- the target protein (CDK) may be captured using a specific antibody.
- use of an anti-CDK1 antibody indicates that all of the CDK1 present in the cell (including CDK alone, complexes of CDK with cyclins and Z or CDK inhibitors, complexes of CDK with other compounds) Can be captured.
- the specific activity calculated by the above equation corresponds to the ratio of the CDK exhibiting the activity among the CDKs present in the cells, and the CDK activity level based on the growth state of the animal cell to be determined is I can say.
- the CDK specific activity thus determined does not depend on the preparation method of the measurement sample. Measurement sample preparation methods, especially measurement samples (cell lysates) prepared from biopsies, are susceptible to the effects of non-cellular tissues, such as extracellular matrix, in the tissues actually collected. Therefore, the significance of using the specific activity or the reciprocal thereof after subtracting such effects is significant, and the correlation with the clinical character is higher than that of the conventional simple activity value.
- the type of CDK for which specific activity is measured may be appropriately selected according to the type of property to be known.
- cancer cells deviate from normal growth control and proliferate actively.Thus, it is considered that the proportion of cells in the S phase and G2 phase is high, and it is considered that cancer occurs in such cases.
- aneuploidy may have passed abnormal M phase or progressed to G1 phase without M phase, Therefore, it is also considered malignant if the proportion of cells present in the M phase is small.
- CDK1 was used as the first cyclin-dependent kinase and CDK2 was used as the second cytaline-dependent kinase, and they were classified into groups according to the magnitude of CDK1 specific activity.
- the specific activity value reflects the cell ratio in S phase. When there are many cells in the S phase, it can be determined that the tissue in which the cells are constituent cells is clinically malignant, that is, a malignant cancer with a poor prognosis that easily metastasizes.
- the existence ratio of the cell cycle at a specific time is estimated from the CDK specific activity profile including two or more types of CDK specific activity, and the degree of malignancy of the cell is determined.
- the specific activity profile of two or more types of CDKs which have been measured in advance using the corresponding normal tissue cells as standard cells, may be determined, and the degree of malignancy may be determined by comparison with the normal cells.
- the ratio of the specific activities of two cyclin-dependent kinases it is preferable to employ the ratio of the specific activities of two cyclin-dependent kinases.
- the property of the cell is determined by comparing the ratio of the specific activities of the two cyclin-dependent kinases to a predetermined threshold value corresponding to the ratio.
- the threshold value used in the cell property determination method of the present invention is appropriately determined depending on the type of the cell to be measured and the determination item.
- the threshold value can be set by selecting a value of the ratio of the specific activity serving as a border for the relevant item from a database of a large number of cells and individuals related to the target item and a database of CDK specific activities of the cell. For example, the ratio of the specific activities of two types of CDKs, which are considered to be correlated, was calculated for tumor cells from multiple patients whose tumors were known by the pathologist to determine the degree of malignancy of the cancer. The median value at which the population can be divided into two equal parts by arranging the ratios in ascending order can be used as the threshold value.
- the determination method of the present invention can also be applied to the sensitivity of a cell to an irritant, not only to the properties of the cell such as proliferation ability and malignancy.
- differences in the efficacy of drugs such as anticancer drugs due to the genetic constitution of patients, which have been pointed out in recent years, are caused by differences in sensitivity of cells to stimulants.
- the intrinsic properties of cells include whether they are sensitive or insensitive to stimulants! / Ivy, and the ratio of the specific activities of the two CDKs is also related to their sensitivity to stimulants. ing.
- the acceptability determination method is based on a CDK profile including a ratio between the expression level and the activity value of the first CDK and a ratio between the expression level and the activity value of the second CDK, and the sensitivity of the cell to the stimulant is determined.
- a CDK profile including a ratio between the expression level and the activity value of the first CDK and a ratio between the expression level and the activity value of the second CDK, and the sensitivity of the cell to the stimulant is determined.
- Examples of the CDK profile include a profile containing CDK specific activity (CDK specific activity profile) and a profile containing a reciprocal of CDK specific activity (reciprocal profile of CDK specific activity).
- the ratio of the specific activity of the first cyclin-dependent kinase to the specific activity of the second cyclin-dependent kinase is compared with a predetermined threshold value.
- the stimulating substance is selected from the group consisting of growth factors, anticancer agents, and mutagenic substances.
- the content of determination and the content of sensitivity differ depending on the type of the stimulus substance. For example, it is determined whether or not an anticancer agent is effective, and whether or not there is a response to a mutagenic substance or a growth factor.
- the threshold value used as a criterion for determination in the cell sensitivity determination method of the present invention is appropriately set according to the type of the stimulant.
- the threshold is set by examining the correlation between the specific activity value of CDK, which serves as a judgment index for cells that have been stocked in advance, and data on whether or not these cells are sensitive to stimulants.
- a threshold that is a boundary is selected.
- the threshold is set based on the relationship between the ratio of the specific activities of the two types of CDKs, which is divided into the group of patients exposed to the stimulant and the group of susceptibility to the stimulus.
- cultured cells of various tumor cells may be stimulated with a stimulant, and the proliferation level and response level to the stimulant may be measured to separate the cells into a sensitive group and a non-sensitive group. It may be set based on the relationship with the ratio of two types of CDK specific activities measured separately! / ⁇
- the value of one or both CDK specific activities itself for determination is very small! /, Or conversely, one or both specific activities. In some cases, the value is so large that the specific activity ratio value is far from the threshold value.
- cells that are judged to be insensitive to the stimulant may have a very small specific activity value of CDK, which is a measurement item.
- the stimulus may be determined by considering the magnitude of the specific activity value of CDK, which is used for the judgment that cannot be made only by the ratio of the specific activity values.
- quality sensitivity is determined. Specifically, a threshold value serving as a judgment index is set for the specific activity value itself, and a judgment is made in consideration of a result of comparison with the threshold value.
- the order of these comparisons is not particularly limited. It is preferable to appropriately determine the handling according to the type. For example, the specific activity value may be compared with a threshold value to determine those which can be clearly determined to be sensitive or insensitive, and then the remaining cells may be determined by comparing the specific activity ratio with the corresponding threshold value. Alternatively, if the cell to be measured is a cell having a very small specific activity value of one or both !, or a cell having a very large specific activity value of one or both, and if the cell is a cell, first determine the specific activity ratio of CDK.
- the specific activity of one or both cells is very small, and the specific activity of one or both cells is very small.
- the determination result based on the comparison between the specific activity ratio and the corresponding threshold may be modified. ,.
- the specific activity value differs depending on the method for measuring the activity and expression level, the type of antibody used for the measurement, and the like. Therefore, the determination method of the present invention based on the comparison with the threshold value includes a method for measuring the specific activity at the time of preparing the database when setting the threshold value and a method for measuring the specific activity of the cell to be determined. Must be matched with
- Surgically collected tissues (2 mm 3 ) or cultured tumor cells shown in Table 2 were used as the biological samples to be measured.
- the biological sample was prepared by adding 0.1 lwZv% Noded P-40 (NP-40) (manufactured by Calbiochem), 50 mM Tris-HCl (pH 7.4), 5 mM EDTA, 50 mM FDTA, sodium
- the cell lysate was removed by aspirating 10 times with a 5 ml syringe equipped with a 23G needle in an ice bath in a lysis buffer containing 100% sodium orthovanadate and 100 ⁇ l Zml of the protease inhibitor cocktail (Sigma).
- the cultured cells were prepared so as to be 1 ⁇ 10 7 cells / 5 ml.
- the insoluble matter was removed by centrifugation at 15,000 rpm for 5 minutes at 4 ° C., and the supernatant (cell lysate) was used as a sample for measurement.
- Sepharose beads manufactured by Bio-Rad
- protein ⁇ specific antibody polyclonal anti-CDK1 antibody or polyclonal anti-CDK2 antibody from Santa Cruz Biotechnology
- the beads were washed three times with a buffer solution (0.1% NP-40, 50 mM Tris-HCl, pH 7.0), and 15 The sample was resuspended in the solution to obtain a sample containing beads to which the target sample containing CDK was bound.
- This sample contains all of CDK alone, cyclin-bound activated CDK, a complex of activated CDK and CDK inhibitor, and a complex of CDK and CDK inhibitor (hereinafter referred to as "CDK group Is captured and bound to the beads.
- CDK group Is captured and bound to the beads.
- the activity of such a CDK group was measured by the following method.
- Histone HI manufactured by Upstate Biotechnology
- a substrate corresponding to CDK1 and CDK2 10 ⁇ g, 5 mM adenosine 5, -0- (8-thiotriphosphate) (ATP-yS, Sigma
- a buffer solution (20 mM Tris-HCl (pH 7.4), 0.1% Triton X-100) was prepared, and this substrate solution was added to the above CDK sample solution to make 501, and 37 ° Incubate with shaking at C for 10 minutes.
- the serine or threon residue of the substrate is phosphorylated by the activated CDK to obtain a monothiophosphorylated substrate.
- the beads were precipitated by centrifugation at 100,000 rpm for 10 seconds, and a supernatant 301 in which monothiophosphoric acid was dissolved was collected.
- incubating at room temperature for 90 minutes at room temperature in a 10 mM eodoacetylfluorescein solution 100 mM Tris-HCl (pH 7.5), ImM EDTA
- the thiophosphoric acid of the monothiophosphoric acid substrate was obtained.
- the sulfur in was fluorescently labeled.
- the reaction between iodoacetylfluorescein and thiophosphoric acid was stopped by adding 6-mercaptoethanol.
- the calibration curve was prepared by measuring the CDK activity using different concentrations of only the active CDK of interest contained in K-562 chronic myeloid leukemia cells. Therefore, the measured CDK activity of 1 U refers to the amount of an enzyme showing an activity equivalent to the enzyme activity (the amount of an enzyme that changes a certain amount of substrate) when 1 ⁇ g of the total protein of K-562 cells is used.
- suction was applied from the bottom surface of the gel, that is, the back surface of the membrane, at a negative pressure of about 200 mmHg for about 15 seconds to adsorb the sample to the membrane.
- a solution of a heron anti-CDK1 antibody or a heron anti-CDK2 antibody (primary antibody) that specifically binds to a sample is injected into each well, and left at room temperature for about 30 minutes.
- a vacuum was applied at a negative pressure of 500 mmHg for about 15 seconds, followed by washing with TBS (25 mM Tris-HCl (pH 7.4), 150 mM NaCl).
- the FITC-labeled streptavidin reagent was injected in an amount of 40 ⁇ l each, and allowed to stand at room temperature for about 30 minutes to label the secondary antibody with FITC. ⁇ Suction at bottom pressure 500mmHg for about 15 seconds Then, the plate was washed with TBS (25 mM Tris-HCl (pH 7.4), 150 mM NaCl).
- the PVDF membrane was removed from the plate, washed with distilled water, and immersed in 20% methanol for 5 minutes. After drying at room temperature for about 15 minutes, the fluorescence intensity of the protein adsorbed on the membrane is analyzed and measured with an image analyzer (Bio-Rad), and the protein is labeled with FITC based on the calibration curve created in advance.
- the protein (CDK1 or CDK2) was quantified (the amount corresponding to the number of CDKs was converted to the weight (mg) of the standard protein).
- the amount of CDK measured in this way is the total amount of CDK group (CDK alone, complex of CDK and cyclin and Z or CDK inhibitor, complex of CDK and other compounds) present in the cells. is there.
- the calibration curve was obtained by preparing solutions of pure recombinant CDK proteins at five concentrations in TBS containing 0.005% NP-40 and 50 ⁇ g / ml BSA in the same manner as described above. The wells that had been treated were injected with 50 1 each, labeled with FITC in the same manner as above, measured for fluorescence intensity, and a relationship between fluorescence intensity and amount was prepared to create a standard curve.
- the CDK specific activity (mUZng or UZng) was calculated from the measured values of the CDK activity and CDK expression amount measured as described above according to the following formula.
- CDK specific activity CDK activity value, CDK expression level
- the target cells were dispersed by trypsin ZEDTA treatment, washed twice with PBS, and centrifuged at 10 OX g at 4 ° C. for 5 minutes to collect cells (2 10 5 to 1 10 6 cells). While stirring the collected cells with a vortex mixer, lml of 70% ethanol pre-cooled to 20 ° C is gradually added to fix the cells, and allowed to react at 4 ° C or -20 ° C for 2 hours or more.
- lml of 70% ethanol pre-cooled to 20 ° C is gradually added to fix the cells, and allowed to react at 4 ° C or -20 ° C for 2 hours or more.
- PI Providiziodide
- FIG. 2 shows the measurement results.
- the vertical axis represents the fluorescence intensity corresponding to the number of cells
- the horizontal axis represents the DNA content.
- the relationship between the DNA content of animal cells and the number of cells is generally linked to the cell cycle, as shown in FIG.
- ModFit manufactured by Verity Software House
- the abundance ratio of cells in the S phase and the G1 phase was examined, and the results are shown in FIG. 2 and 4, KATOIII, K562, and Colo205 cells showed a high S-phase abundance, and ⁇ , Colo205, and HeLa cells showed aneuploidy (particularly aneuploi dy).
- a thin black bar indicates CDK2 specific activity
- a thick white bar indicates CDK1 specific activity
- a left vertical axis indicates CDK1 specific activity
- a right vertical axis indicates CDK2 specific activity.
- the CDK1 specific activity Focusing on the magnitude of the CDK1 specific activity value, the CDK1 specific activity is relatively low, and the group ( ⁇ , K—562, Colo205, HeLa, MCF-7 Itoda vesicle) and it relatively high ⁇ group (SW480, SKBr3, T47D).
- the magnitude of the CDK2 specific activity and the ability to measure the DNA content correspond to the large proportion of cells in the S phase at which the ability to measure the DNA content is also obtained.
- the magnitude of CDK2 specific activity alone cannot correspond to the S phase abundance, but first, after grouping based on CDK1 specific activity, the magnitude of CDK2 specific activity was large. Can be associated with cellular malignancy.
- Example 2 Relationship between the judgment of a pathologist and the CDK specific activity profile of a biopsy sample
- Results of biopsy samples from 77 actual breast cancer patients (No. 1 to 77) determined by a pathologist (TNM classification, lymph node metastasis status, cancer tissue size, presence or absence of recurrence for 5 years after surgery, Table 3 and Table 4 show the recurrence locations). All 77 have early stage breast cancer (Stagel or ⁇ ).
- a measurement sample was prepared according to the above method from a biopsy sample collected from 126 breast cancer patients, and CDK1 specific activity and CDK2 specific activity were measured.
- the CDK2 specific activity / CDK1 specific activity of the measured cancer population was also sorted in order of decreasing power, and the value that allowed the population to be divided into 63:63 was defined as the ratio threshold.
- the threshold value is 46, and the CDK2 specific activity value is determined as ZCDK1 specific activity value is smaller than the threshold value (46), the risk of recurrence is low (low risk), and the CDK2 specific activity ZCDK1 specific activity value ) In the above cases, the risk of recurrence is determined to be high (high risk).
- the scale of the CDK2 specific activity was set to be approximately 46 times the CDK specific activity.
- a graph showing the results of the CDK specific activity profile was created.
- Fig. 6 shows the results of the CDK profiles of patients No. 1 to 42 judged to be in the low-risk group
- Fig. 7 shows the results of CDK profiles of patients No. 43 to 77 judged to be in the high-risk group
- CDK1 Low specific activity High CDK2 specific activity indicates high cancer malignancy.
- specific activity of CDK2 is low and the specific activity of CDK1 is high, the malignancy of the cancer is low.
- CDK2 specific activity is as high (eg, No. 38 and No. 67)
- cancer with relatively large CDKl specific activity is said to have low malignancy.
- the characteristics and malignancy of the cancer can be known from the comparison result with a predetermined threshold value determined in advance.
- a measurement sample was prepared according to the above-mentioned method using the breast cancer tissue collected before the anticancer drug treatment from 1000 breast cancer patients treated with the taxane-based anticancer drug, and the activity and expression level of each of CDK1 and CDK2 were measured to determine the specific activity. Calculated.
- the tumors are classified into cases where the tumor has shrunk and cases where the tumor has not shrunk.
- CDK2 specific activity / CDK1 specific activity ratio threshold was set. The specific activity ratio threshold was 16.
- the tumor size is reduced or not reduced based on the CDK1 specific activity value or CDK2 specific activity value.
- a threshold was set so that the groups could be classified.
- the threshold values for the CDK1 specific activity value were 20, and the threshold values for the CDK2 specific activity value were 500 and 10,000.
- CDK1 specific activity and CDK2 specific activity are compared with a threshold value. If the CDK1 specific activity is less than 20 (CDK1 specific activity value 20) and the CDK2 specific activity value is less than 00 (CDK2 specific activity value 500) Is judged as insensitive, and the insensitive prediction group Classified as a loop. On the other hand, if the CDK2 specific activity value exceeds 10,000 (CDK1 specific activity value> 10000), it is determined to be susceptible and is classified into a susceptibility prediction group.
- the CDK2 specific activity / CDK1 specific activity was compared with a threshold (16), and the value of the ratio was 16 or more.
- the case of is judged as a susceptible group, and the case of less than 16 is judged as an insensitive group.
- the specific activity of CDK2 was determined to be infinite for convenience. In other words, in this case, since the specific activity ratio threshold was 16 or more, the sensitivity was determined.
- a measurement sample is prepared according to the above method using breast cancer tissues collected from breast cancer patients A to I, and the activity and CDK expression level of each of CDK1 and CDK2 are measured to determine the specific activity. Calculated.
- FIG. 8 shows a CDK specific activity profile showing the relationship between CDK1 specific activity and CDK2 specific activity (vertical axis) for patients A to I (horizontal axis).
- the vertical axis scale of CDK2 specific activity was set to 16 times the vertical axis scale of CDK1 specific activity.
- Docetaxel-insensitive predictive group patients A, B, C
- Docetaxel Susceptibility Prediction Group Patients D, E, F, G, H, I
- the anticancer drug docetaxel (manufactured by Aventice Co., Ltd.) was administered four times at an interval of 3 to 4 weeks at a dose of 60 mgZm 2 (body surface area). After the administration, the size of the tumor was reduced, and it was examined whether the size of the tumor was reduced.
- a measurement sample is prepared according to the above method using breast cancer tissues collected from breast cancer patients J to P, and the activity and expression level of each of CDK1 and CDK2 are measured to calculate the specific activity. did.
- FIG. 9 shows a CDK specific activity profile showing the relationship between CDK1 specific activity and CDK2 specific activity (vertical axis) for patients J to P (horizontal axis).
- the vertical axis scale of CDK2 specific activity was set to 16 times the vertical axis scale of CDK1 specific activity.
- the results of the classification of patients J to P into the group that is predicted and determined as paclitaxel susceptibility and the group that is predicted and determined as insensitive are as follows.
- Paclitaxel Susceptibility Prediction Group Patients L, M, N, O, P
- an anticancer drug paclitaxel (manufactured by Bristol Pharmaceutical Co., Ltd.) was gZm 2 (body surface area) was administered once a week, and this was continued for 12 weeks before examining the power of the reduction in tumor size. The determination of whether the tumor size was reduced or not was based on the same criteria as for docetaxel.
- the determination result regarding the characteristics of cells, particularly the malignancy of cancer based on the determination method of the present invention has a high correlation with the determination result of a clinician in the medical field, it is possible to prevent cell proliferation control dysfunction such as cancer. It is applicable as a definitive diagnosis of the disease caused. In addition, it can be used for research on dysregulation of the proliferation function of various mammalian cells other than human diseases.
- the method of the present invention for determining the sensitivity of animal cells to stimulants can be used as a method for examining the effects of cell proliferation on various drugs and drugs, such as anticancer agents, growth factors, and mutagenic substances. It can be used to determine the efficacy of a drug such as an anticancer drug depending on the type of cancer cells, or the efficacy of a drug such as an anticancer drug depending on the individual. This makes it possible to predict whether it is effective to select an anticancer drug treatment before actually administering the treatment to a patient, and thus the method for determining sensitivity according to the present invention can be used as a guide for selecting an appropriate treatment method. Can be used as a mark.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT05743830T ATE489622T1 (de) | 2004-05-31 | 2005-05-30 | Verfahren zur beurteilung der malignität einer säuger-krebszelle |
US11/597,414 US8921057B2 (en) | 2004-05-31 | 2005-05-30 | Method of assessing properties of mammalian cells, and method of diagnosing cancer using the same |
EP05743830A EP1767647B1 (en) | 2004-05-31 | 2005-05-30 | Method of judging malignancy of a mammalian cancer cell |
JP2006513979A JP4787153B2 (ja) | 2004-05-31 | 2005-05-30 | 癌の再発のしやすさの試験方法及び抗癌剤に対する感受性の試験方法 |
DE602005024964T DE602005024964D1 (de) | 2004-05-31 | 2005-05-30 | Verfahren zur beurteilung der malignität einer säuger-krebszelle |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004160389 | 2004-05-31 | ||
JP2004-160389 | 2004-05-31 | ||
JP2004375639 | 2004-12-27 | ||
JP2004-375639 | 2004-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005116241A1 true WO2005116241A1 (ja) | 2005-12-08 |
Family
ID=35450902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/009847 WO2005116241A1 (ja) | 2004-05-31 | 2005-05-30 | 哺乳動物細胞の性質判定方法及びこれを用いた癌の診断方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8921057B2 (ja) |
EP (1) | EP1767647B1 (ja) |
JP (1) | JP4787153B2 (ja) |
AT (1) | ATE489622T1 (ja) |
DE (1) | DE602005024964D1 (ja) |
WO (1) | WO2005116241A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008220299A (ja) * | 2007-03-14 | 2008-09-25 | Sysmex Corp | 癌の診断支援装置 |
EP2028600A1 (en) | 2007-08-24 | 2009-02-25 | Sysmex Corporation | Diagnosis support system for cancer, diagnosis support for information providing method for cancer, and computer program product |
JP2009072181A (ja) * | 2007-08-24 | 2009-04-09 | Sysmex Corp | がんの診断支援システム及びがんの診断支援情報提供方法 |
JP2009082109A (ja) * | 2007-10-02 | 2009-04-23 | Sysmex Corp | がんの診断支援システム、アンスラサイクリン系抗がん剤の有効性予測システム及びアンスラサイクリン系抗がん剤の有効性の予測方法 |
JP2009089672A (ja) * | 2007-10-10 | 2009-04-30 | Sysmex Corp | がんの再発リスクの判定方法 |
JP2009232816A (ja) * | 2008-03-28 | 2009-10-15 | Sysmex Corp | アンスラサイクリン系抗がん剤治療の有効性を判定する方法、及びアンスラサイクリン系抗がん剤治療の有効性の診断支援方法 |
JP2009232815A (ja) * | 2008-03-28 | 2009-10-15 | Sysmex Corp | 癌の再発リスクを判定する方法及び癌の再発リスク診断の支援方法 |
JP2012228233A (ja) * | 2011-04-27 | 2012-11-22 | Sysmex Corp | 併用化学療法の奏効性判定方法、奏効性判定プログラム及び奏効性判定装置 |
JP2020162420A (ja) * | 2019-03-28 | 2020-10-08 | シスメックス株式会社 | サイクリン依存性キナーゼ4/6阻害剤の感受性を判定するための方法、試薬キット、装置及びコンピュータプログラム |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1840221A1 (en) * | 2006-03-31 | 2007-10-03 | Sysmex Corporation | Method for measuring kinase activity |
JP4989127B2 (ja) * | 2006-06-30 | 2012-08-01 | シスメックス株式会社 | チロシンキナーゼの活性測定方法及びチロシンキナーゼの基質 |
JP5283872B2 (ja) * | 2006-09-27 | 2013-09-04 | シスメックス株式会社 | 腫瘍細胞に対する阻害剤の増殖抑制効果を評価する方法、及び腫瘍細胞の増殖を阻害する化合物をスクリーニングする方法 |
JP2009240238A (ja) * | 2008-03-31 | 2009-10-22 | Sysmex Corp | アンスラサイクリン系抗がん剤に対するがん細胞の感受性の判定方法及び判定装置 |
JP2010057486A (ja) * | 2008-09-02 | 2010-03-18 | Sysmex Corp | 化学療法に対するがん患者の応答の予測方法 |
AT508680B1 (de) * | 2009-05-19 | 2011-03-15 | Onkotec Gmbh | Verfahren zur qualitativen und/oder quantitativen bestimmung von tumorzellen |
JP6002379B2 (ja) | 2011-11-29 | 2016-10-05 | シスメックス株式会社 | 癌の再発リスクの判定方法及びその利用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11166031A (ja) * | 1997-08-12 | 1999-06-22 | Emtec Magnetics Gmbh | 溶媒の不存在下に製造し得るポリウレタンおよび磁気記録媒体用結合剤としてのその用途 |
JP2002335997A (ja) * | 2001-02-14 | 2002-11-26 | Sysmex Corp | 細胞周期調節因子の活性の測定法とそれを用いた癌の診断法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69707318T2 (de) * | 1996-02-08 | 2002-02-21 | Arakis Ltd | Trennung von 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylexancarbonsäure |
JPH11166931A (ja) | 1997-12-05 | 1999-06-22 | Sysmex Corp | 生体成分の量的あるいは質的異常を検出する方法 |
AU741632B2 (en) | 1998-02-18 | 2001-12-06 | Theryte Limited | Treating cancer |
DE19829473C2 (de) | 1998-07-01 | 2000-08-10 | Magnus Von Knebel Doeberitz Ch | Verfahren zur frühen Diagnose von Carcinomen |
EP1609854B1 (en) | 2001-02-14 | 2008-04-30 | Sysmex Corporation | Method for determining activity of cell cycle regulatory factor and method for diagnosing cancer using the same |
DK1388734T3 (da) | 2002-08-01 | 2004-05-03 | Mtm Lab Ag | Metode til opløsningsbaseret diagnose |
DE602004025676D1 (de) | 2003-02-26 | 2010-04-08 | Sysmex Corp | Verfahren zur untersuchung einer zelle |
US7957910B2 (en) * | 2005-01-31 | 2011-06-07 | Sysmex Corporation | Method for predicting effectiveness of chemotherapy |
-
2005
- 2005-05-30 DE DE602005024964T patent/DE602005024964D1/de active Active
- 2005-05-30 US US11/597,414 patent/US8921057B2/en not_active Expired - Fee Related
- 2005-05-30 EP EP05743830A patent/EP1767647B1/en not_active Not-in-force
- 2005-05-30 WO PCT/JP2005/009847 patent/WO2005116241A1/ja not_active Application Discontinuation
- 2005-05-30 JP JP2006513979A patent/JP4787153B2/ja active Active
- 2005-05-30 AT AT05743830T patent/ATE489622T1/de not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11166031A (ja) * | 1997-08-12 | 1999-06-22 | Emtec Magnetics Gmbh | 溶媒の不存在下に製造し得るポリウレタンおよび磁気記録媒体用結合剤としてのその用途 |
JP2002335997A (ja) * | 2001-02-14 | 2002-11-26 | Sysmex Corp | 細胞周期調節因子の活性の測定法とそれを用いた癌の診断法 |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008220299A (ja) * | 2007-03-14 | 2008-09-25 | Sysmex Corp | 癌の診断支援装置 |
EP2028600A1 (en) | 2007-08-24 | 2009-02-25 | Sysmex Corporation | Diagnosis support system for cancer, diagnosis support for information providing method for cancer, and computer program product |
JP2009072181A (ja) * | 2007-08-24 | 2009-04-09 | Sysmex Corp | がんの診断支援システム及びがんの診断支援情報提供方法 |
US8921114B2 (en) | 2007-08-24 | 2014-12-30 | Sysmex Corporation | Diagnosis support system for cancer, diagnosis support information providing method for cancer, and computer program product |
JP2009082109A (ja) * | 2007-10-02 | 2009-04-23 | Sysmex Corp | がんの診断支援システム、アンスラサイクリン系抗がん剤の有効性予測システム及びアンスラサイクリン系抗がん剤の有効性の予測方法 |
JP2009089672A (ja) * | 2007-10-10 | 2009-04-30 | Sysmex Corp | がんの再発リスクの判定方法 |
JP2009232816A (ja) * | 2008-03-28 | 2009-10-15 | Sysmex Corp | アンスラサイクリン系抗がん剤治療の有効性を判定する方法、及びアンスラサイクリン系抗がん剤治療の有効性の診断支援方法 |
JP2009232815A (ja) * | 2008-03-28 | 2009-10-15 | Sysmex Corp | 癌の再発リスクを判定する方法及び癌の再発リスク診断の支援方法 |
JP2012228233A (ja) * | 2011-04-27 | 2012-11-22 | Sysmex Corp | 併用化学療法の奏効性判定方法、奏効性判定プログラム及び奏効性判定装置 |
JP2020162420A (ja) * | 2019-03-28 | 2020-10-08 | シスメックス株式会社 | サイクリン依存性キナーゼ4/6阻害剤の感受性を判定するための方法、試薬キット、装置及びコンピュータプログラム |
US11639940B2 (en) | 2019-03-28 | 2023-05-02 | Sysmex Corporation | Method for determining sensitivity of cyclin-dependent kinase 4/6 inhibitor |
Also Published As
Publication number | Publication date |
---|---|
ATE489622T1 (de) | 2010-12-15 |
EP1767647A1 (en) | 2007-03-28 |
EP1767647A4 (en) | 2007-08-29 |
US20070231837A1 (en) | 2007-10-04 |
JP4787153B2 (ja) | 2011-10-05 |
JPWO2005116241A1 (ja) | 2008-04-03 |
US8921057B2 (en) | 2014-12-30 |
DE602005024964D1 (de) | 2011-01-05 |
EP1767647B1 (en) | 2010-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005116241A1 (ja) | 哺乳動物細胞の性質判定方法及びこれを用いた癌の診断方法 | |
Yoshimura et al. | Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells | |
Signoretti et al. | Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer | |
Baljinnyam et al. | Exchange protein directly activated by cyclic AMP increases melanoma cell migration by a Ca2+-dependent mechanism | |
Liu et al. | Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis | |
Palou et al. | Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guerin | |
CN101990577A (zh) | 鉴定肺病药物开发的新途径 | |
US9651554B2 (en) | Molecular diagnostic methods for predicting brain metastasis of breast cancer | |
Wei et al. | Relationship of CD44+ CD24-/low breast cancer stem cells and axillary lymph node metastasis | |
Ammendola et al. | Tryptase-positive mast cells and angiogenesis in keloids: a new possible post-surgical target for prevention | |
Albahde et al. | Upregulated expression of TUBA1C predicts poor prognosis and promotes oncogenesis in pancreatic ductal adenocarcinoma via regulating the cell cycle | |
Miao et al. | SCC-S2 is overexpressed in colon cancers and regulates cell proliferation | |
Fröbom et al. | Biochemical inhibition of DOG1/TMEM16A achieves antitumoral effects in human gastrointestinal stromal tumor cells in vitro | |
US20120302624A1 (en) | Biomarker for identifying subgroup of early-stage lung adenocarcinoma patients | |
Chung et al. | Multi‐kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin‐related protein 1 | |
Scopetti et al. | INSL4 as prognostic marker for proliferation and invasiveness in Non-Small-Cell Lung Cancer | |
Li et al. | Ad5-EMC6 mediates antitumor activity in gastric cancer cells through the mitochondrial apoptosis pathway | |
JP4944446B2 (ja) | 抗がん剤治療の有効性予測方法 | |
Jia et al. | Identification of prognosis-related proteins in advanced gastric cancer by mass spectrometry-based comparative proteomics | |
Wang et al. | Predictive and prognostic biomarkers of bone metastasis in breast cancer: current status and future directions | |
Luo et al. | The clinicopathological and prognostic significance of P27kip in hepatocellular carcinoma patients: A systemic review and meta-analysis | |
ES2354616T3 (es) | Método para evaluar la malignidad de una célula de mamífero cancerosa. | |
CN111289749B (zh) | C型1类尼曼-匹克蛋白检测物在制备筛查肝细胞癌产品中的应用 | |
Zhou et al. | NEK2 Serves as a Novel Biomarker and Enhances the Tumorigenicity of Clear-CellRenal-Cell Carcinoma by Activating WNT/β-Catenin Pathway | |
Goto et al. | The prognosis in spindle‐cell sarcoma depends on the expression of cyclin‐dependent kinase inhibitor p27Kip1 and cyclin E |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006513979 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11597414 Country of ref document: US Ref document number: 2007231837 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580016823.2 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005743830 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005743830 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11597414 Country of ref document: US |